<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00165776</url>
  </required_header>
  <id_info>
    <org_study_id>E2014-J081-131</org_study_id>
    <nct_id>NCT00165776</nct_id>
  </id_info>
  <brief_title>Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      To evaluate efficacy and safety of E2014 (2500U, 5000U, 10000U, placebo) in a multicenter,
      randomized, double-blind, parallel group comparative study by intramuscularly administering
      to patients with spasmodic torticollis. Primary endpoint for efficacy evaluation is changes
      in TWSTRS total scores from baseline measured at Week 4 and the clinical recommended dose
      will be examined with Williams multiple comparison. For safety evaluation, an inter group
      comparison (active drug and placebo) will be performed mainly focusing on incidence of
      adverse events, adverse drug reactions, and abnormal changes in laboratory parameters.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Treatment</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>The TWSTRS-Total score is the sum of scores of the three components of the scale:
TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)
TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)
TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).
The TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Patient Global Assessment - Visual Analog Scale (PtGA-VAS) at Week 4 After Treatment</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Change from Baseline in PtGA-VAS is computed as Week 4 value minus baseline value. A negative value in change from baseline indicates an improvement. Participants answered: &quot;Considering all the ways your cervical dystonia affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Physician Global Assessment Disease Assessment - Visual Analog Scale (PGA-VAS) at Week 4 After Treatment</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Change from Baseline in PGA-VAS (0 to 100 mm visual analog scale, 0 being no symptoms and 100 being severe symptoms) is computed as Week 4 value minus baseline value. A negative value in change from baseline indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the TWSTRS - Functional Disability Score at Week 4 After Treatment</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>TWSTRS-Disability score which ranges from 0 (=no disability)to 30 (=maximum disability). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the TWSTRS - Pain Score at Week 4 After Treatment</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the TWSTRS - Severity Score at Week 4 After Treatment</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Patient Pain Assessment (VAS) at Week 4 After Treatment</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Change from Baseline in Patient's Pain Assessment-VAS is computed as Week 4 value minus baseline value. A negative value in change from baseline indicates an improvement. The patient's assessment of pain was performed using a 100 mm VAS)ranging from no pain (0) to unbearable pain (100). The distance in mm from the left edge of the scale was measured. A negative change from Baseline score indicates improvement in pain intensity.</description>
  </secondary_outcome>
  <enrollment type="Actual">133</enrollment>
  <condition>Cervical Dystonia</condition>
  <condition>Spasmodic Torticollis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOTULINUM TOXIN TYPE B</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who can give written informed consent and aged between greater than or equal
             to 20 years and less than 75 years at the time of obtaining prior consent
             (irrespective of gender).

          -  Patients with dystonic symptoms at least 2 or more lesions in the following cervical
             muscles.

          -  Sternocleidomastoid

          -  Scalenus complex (scalenus anterior, scalenus medius, and scalenus posterior)

          -  Trapezius

          -  Levator scapulae

          -  Splenius capitis

          -  Semispinalis capitis

          -  Patients who persistently have symptoms in the above (2) for 1 year or longer.

          -  Patients weighing greater than or equal to 40 kg.

          -  Patients whose TWSTRS total score at baseline is greater than or equal to 20.

          -  Patients whose TWSTRS-severity score at baseline is greater than or equal to 10.

          -  Patients whose TWSTRS-disability score at baseline is greater than or equal to 3.

          -  Patients whose TWSTRS-pain score at baseline is greater than or equal to 1.

          -  Patients who are judged to be eligible for study entry by the investigator or
             subinvestigator based on their physical and neurological findings, laboratory
             parameters, and ECG results.

        Exclusion Criteria:

          -  Patients who are botulinum toxin-resistant in previous exposures (primary
             no-responder*)

             *If patients who were once responder to botulinum toxin treatment but thereafter
             became non-responder can be included in this study.

          -  Patients whose passive range of motion in the neck is significantly narrowed due to
             cervical contracture or spondylosis.

          -  Patients having only pure retrocollis- or anterocollis-associated symptoms.

          -  Patients who received botulinum toxin agents within 4 months prior to study treatment
             of E2014, or those who show carry-over effect of previous treatment with botulinum
             toxin at the time of starting study administration even though the previous treatment
             was given 4 months or earlier.

          -  Patients who were treated with narcotics or antibiotics that may potentiate effects of
             muscle relaxation (spectinomycin hydrochloride preparations, aminoglycosides,
             polypeptides, tetracyclines, lincomycins) within 4 months prior to study treatment.

          -  Patients who started or altered the dose levels of the following agents
             (musculoskeletal relaxants, antispasm drugs, strong tranquilizers, benzodiazepines
             including similar drugs, anticholinergic drugs, antiparkinsonian drugs,
             antidepressants) within 4 weeks prior to study treatment.

          -  Patients who received medical care(s) other than pharmacotherapies (surgical
             interventions, MAB, acupuncture, relaxation, etc.) prior to study treatment showing
             carry-over effect of these cares or unstable condition at the time of starting study
             treatment.

          -  Patients who have a history of myectomy or neurectomy in the neck and/or shoulder.

          -  Patients who have a history of hypersensitivity to E2014's ingredients (botulinum
             toxin type B, human serum albumin, sodium succinate buffer solution), or other type of
             botulinum toxins.

          -  Patients with complication(s) or history of serious neurological or musculoskeletal
             disease (myasthenia, amyotrophic lateral sclerosis, etc.), cardiovascular disease
             (acute myocardial infarction, etc.), respiratory disease (COPD, etc.), renal disease
             (acute or chronic renal failure, etc.), hepatic disease (cirrhosis, etc.),
             gastrointestinal disease (paralytic ileus, etc.), dermatological disease (toxic
             epidermal necrosis, etc.), psychiatric disease (schizophrenia, alcohol or drug
             dependence, etc.), hematological disease (aplastic anemia, etc.), and/or infectious
             disease (hepatitis, syphilis, AIDS, etc.).

          -  Patients with complication or history of malignant tumor(s).

          -  Patients who participated in another clinical study within 30 days prior to obtaining
             informed consent for this study.

          -  Women of pregnant, childbearing potential, childbearing intension during the study
             period, or lactating.

          -  Others who are judged to be ineligible for study entry by the investigator or
             subinvestigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Ichihara</city>
        <state>Chiba -prefecture</state>
        <zip>290-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka -prefecture</state>
        <zip>807-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0814</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <state>Kagoshima-prefecture</state>
        <zip>890-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa -prefecture</state>
        <zip>228-0829</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa-prefecture</state>
        <zip>216-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsumoto</city>
        <state>Nagano-prefecture</state>
        <zip>390-0802</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kashihara</city>
        <state>Nara-prefecture</state>
        <zip>634-0813</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moriguchi</city>
        <state>Osaka</state>
        <zip>570-0074</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <zip>590-0132</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saitama</city>
        <state>Saitama-prefecture</state>
        <zip>338-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saitama</city>
        <state>Saitama-prefecture</state>
        <zip>338-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama-prefecture</state>
        <zip>359-1141</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka-prefecture</state>
        <zip>430-0906</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokushima</city>
        <state>Tokushima-prefecture</state>
        <zip>770-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>153-0044</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-0054</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <zip>601-1434</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>553-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <results_first_submitted>July 12, 2013</results_first_submitted>
  <results_first_submitted_qc>November 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 8, 2014</results_first_posted>
  <last_update_submitted>February 6, 2014</last_update_submitted>
  <last_update_submitted_qc>February 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Torticollis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>rimabotulinumtoxinB</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>130 patients (33 of the placebo group, 34 of the 2500U group, 32 of the 5000U group, and 31 of the 10000U group) received study treatment, but after randomization, 3 patients (2 of the placebo group and 1 of the 5000U group) had no treatment. The reason was that 2 of them requested withdrawal from the study and 1 ceased to return for visits.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>placebo/ 2 mL was intramuscularly injected to cervical muscles as a single dose</description>
        </group>
        <group group_id="P2">
          <title>E2014 2,500 U</title>
          <description>2,500 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
        </group>
        <group group_id="P3">
          <title>E2014 5,000 U</title>
          <description>5,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
        </group>
        <group group_id="P4">
          <title>E2014 10,000 U</title>
          <description>10,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Worsening of Cervical Dystonia</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>After randomized to the treatment groups, 3 patients (2 of the placebo group and 1 of the 5000U group) had no treatment. The reason was that 2 of them requested withdrawal from the study and 1 ceased to return for visits.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>placebo/ 2 mL was intramuscularly injected to cervical muscles as a single dose. Two subjects from the placebo group did not receive treatment after randomization.</description>
        </group>
        <group group_id="B2">
          <title>E2014 2,500 U</title>
          <description>2,500 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
        </group>
        <group group_id="B3">
          <title>E2014 5,000 U</title>
          <description>5,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose. One subject from the 5,000 U/2 mL did not receive treatment after randomization.</description>
        </group>
        <group group_id="B4">
          <title>E2014 10,000 U</title>
          <description>10,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="31"/>
            <count group_id="B5" value="130"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 to less than 60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than or equal to 60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Patient Global Assessment - Visual Analog Scale (PtGA-VAS) at Week 4 After Treatment</title>
        <description>Change from Baseline in PtGA-VAS is computed as Week 4 value minus baseline value. A negative value in change from baseline indicates an improvement. Participants answered: &quot;Considering all the ways your cervical dystonia affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo/ 2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O2">
            <title>E2014 2,500 U</title>
            <description>2,500 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O3">
            <title>E2014 5,000 U</title>
            <description>5,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O4">
            <title>E2014 10,000 U</title>
            <description>10,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Patient Global Assessment - Visual Analog Scale (PtGA-VAS) at Week 4 After Treatment</title>
          <description>Change from Baseline in PtGA-VAS is computed as Week 4 value minus baseline value. A negative value in change from baseline indicates an improvement. Participants answered: &quot;Considering all the ways your cervical dystonia affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.</description>
          <population>FAS</population>
          <units>Millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="3.2"/>
                    <measurement group_id="O2" value="11.9" spread="2.6"/>
                    <measurement group_id="O3" value="9.9" spread="3"/>
                    <measurement group_id="O4" value="13.3" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Physician Global Assessment Disease Assessment - Visual Analog Scale (PGA-VAS) at Week 4 After Treatment</title>
        <description>Change from Baseline in PGA-VAS (0 to 100 mm visual analog scale, 0 being no symptoms and 100 being severe symptoms) is computed as Week 4 value minus baseline value. A negative value in change from baseline indicates an improvement.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo/ 2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O2">
            <title>E2014 2,500 U</title>
            <description>2,500 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O3">
            <title>E2014 5,000 U</title>
            <description>5,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O4">
            <title>E2014 10,000 U</title>
            <description>10,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Physician Global Assessment Disease Assessment - Visual Analog Scale (PGA-VAS) at Week 4 After Treatment</title>
          <description>Change from Baseline in PGA-VAS (0 to 100 mm visual analog scale, 0 being no symptoms and 100 being severe symptoms) is computed as Week 4 value minus baseline value. A negative value in change from baseline indicates an improvement.</description>
          <population>FAS</population>
          <units>Millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="2.2"/>
                    <measurement group_id="O2" value="10.6" spread="2.9"/>
                    <measurement group_id="O3" value="11.2" spread="2.6"/>
                    <measurement group_id="O4" value="16.9" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Treatment</title>
        <description>The TWSTRS-Total score is the sum of scores of the three components of the scale:
TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)
TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)
TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).
The TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>Full Analysis Set (FAS) population: All subjects who received study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo/ 2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O2">
            <title>E2014 2,500 U</title>
            <description>2,500 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O3">
            <title>E2014 5,000 U</title>
            <description>5,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O4">
            <title>E2014 10,000 U</title>
            <description>10,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Treatment</title>
          <description>The TWSTRS-Total score is the sum of scores of the three components of the scale:
TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)
TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)
TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).
The TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
          <population>Full Analysis Set (FAS) population: All subjects who received study treatment</population>
          <units>Points on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="1.3"/>
                    <measurement group_id="O2" value="8.9" spread="1.8"/>
                    <measurement group_id="O3" value="7.6" spread="1.6"/>
                    <measurement group_id="O4" value="10.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the TWSTRS - Functional Disability Score at Week 4 After Treatment</title>
        <description>TWSTRS-Disability score which ranges from 0 (=no disability)to 30 (=maximum disability). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo/ 2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O2">
            <title>E2014 2,500 U</title>
            <description>2,500 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O3">
            <title>E2014 5,000 U</title>
            <description>5,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O4">
            <title>E2014 10,000 U</title>
            <description>10,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the TWSTRS - Functional Disability Score at Week 4 After Treatment</title>
          <description>TWSTRS-Disability score which ranges from 0 (=no disability)to 30 (=maximum disability). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
          <population>FAS</population>
          <units>Points on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.7"/>
                    <measurement group_id="O2" value="2.5" spread="0.6"/>
                    <measurement group_id="O3" value="1.9" spread="0.8"/>
                    <measurement group_id="O4" value="3.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the TWSTRS - Pain Score at Week 4 After Treatment</title>
        <description>TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo/ 2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O2">
            <title>E2014 2,500 U</title>
            <description>2,500 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O3">
            <title>E2014 5,000 U</title>
            <description>5,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O4">
            <title>E2014 10,000 U</title>
            <description>10,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the TWSTRS - Pain Score at Week 4 After Treatment</title>
          <description>TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
          <population>FAS</population>
          <units>Points on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.4"/>
                    <measurement group_id="O2" value="2.9" spread="0.7"/>
                    <measurement group_id="O3" value="2" spread="0.7"/>
                    <measurement group_id="O4" value="2.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the TWSTRS - Severity Score at Week 4 After Treatment</title>
        <description>TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo/ 2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O2">
            <title>E2014 2,500 U</title>
            <description>2,500 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O3">
            <title>E2014 5,000 U</title>
            <description>5,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O4">
            <title>E2014 10,000 U</title>
            <description>10,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the TWSTRS - Severity Score at Week 4 After Treatment</title>
          <description>TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
          <population>FAS</population>
          <units>Points on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.6"/>
                    <measurement group_id="O2" value="3.5" spread="0.8"/>
                    <measurement group_id="O3" value="3.7" spread="0.7"/>
                    <measurement group_id="O4" value="4.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Patient Pain Assessment (VAS) at Week 4 After Treatment</title>
        <description>Change from Baseline in Patient's Pain Assessment-VAS is computed as Week 4 value minus baseline value. A negative value in change from baseline indicates an improvement. The patient's assessment of pain was performed using a 100 mm VAS)ranging from no pain (0) to unbearable pain (100). The distance in mm from the left edge of the scale was measured. A negative change from Baseline score indicates improvement in pain intensity.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo/ 2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O2">
            <title>E2014 2,500 U</title>
            <description>2,500 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O3">
            <title>E2014 5,000 U</title>
            <description>5,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
          <group group_id="O4">
            <title>E2014 10,000 U</title>
            <description>10,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Patient Pain Assessment (VAS) at Week 4 After Treatment</title>
          <description>Change from Baseline in Patient's Pain Assessment-VAS is computed as Week 4 value minus baseline value. A negative value in change from baseline indicates an improvement. The patient's assessment of pain was performed using a 100 mm VAS)ranging from no pain (0) to unbearable pain (100). The distance in mm from the left edge of the scale was measured. A negative change from Baseline score indicates improvement in pain intensity.</description>
          <population>FAS</population>
          <units>Millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" spread="4.1"/>
                    <measurement group_id="O2" value="-15" spread="4.5"/>
                    <measurement group_id="O3" value="-13.4" spread="4.7"/>
                    <measurement group_id="O4" value="-8.7" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to last observation carried forward</time_frame>
      <desc>130 patients (33 of the placebo group, 34 of the 2500U group, 32 of the 5000U group, and 31 of the 10000U group) received study treatment, but after randomization, 3 patients (2 of the placebo group and 1 of the 5000U group) had no treatment. The reason was that 2 of them requested withdrawal from the study and 1 ceased to return for visits.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>placebo/ 2 mL was intramuscularly injected to cervical muscles as a single dose</description>
        </group>
        <group group_id="E2">
          <title>E2014 2,500 U</title>
          <description>2,500 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
        </group>
        <group group_id="E3">
          <title>E2014 5,000 U</title>
          <description>5,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
        </group>
        <group group_id="E4">
          <title>E2014 10,000 U</title>
          <description>10,000 U/2 mL was intramuscularly injected to cervical muscles as a single dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pelvic Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Glucose Urine Present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hiroki Shimizu, Study Director</name_or_title>
      <organization>Eisai Co., Ltd.</organization>
      <phone>+81-3-3817-5245</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

